Pagliusi Sonia R, Garland Suzanne M
Department of Immunizations, Vaccines and Biologicals, World Health Organization, Av Appia 20, 1211 Geneva 27, Switzerland.
Dis Markers. 2007;23(4):283-96. doi: 10.1155/2007/591826.
Human papillomavirus is the commonest genital viral infection in healthy sexually active subjects, and the presence of chronic or persistent HPV types in genital cells may constitute a prognostic marker of underlying, or predict future HPV-associated diseases. A variety of novel tests for detecting the presence of oncogenic HPV types in biological specimens have been reported. These are based on the various stages of infection and viral life cycle. HPV infects squamous epithelium with expression of various gene products intimately linked to epithelial cell differentiation. Hence, there are basically three classes of detectable markers directly derived from HPVs: molecular markers based on detection of nucleic acid sequences, serological markers based on detection of antibodies against viral proteins, and cellular markers based on detection of proteins expressed intracellularly, upon either infection or carcinogenesis. The nature of various assays and the development of international standard reagents for qualitative and quantitative assessment of assay performance are outlined. There is an increasing demand to develop standard tools to assess the quality of HPV detection systems, for regulatory and clinical management purposes. International standard reagents for HPV will help defining the analytical sensitivity and specificity of various detection methods, and will allow assuring that laboratory services used to evaluate disease burden, HPV vaccines, and cancer prevention strategies are accurate and comparable worldwide. The advancement of prophylactic vaccine candidates against HPV infections and related diseases stresses the increasing importance of HPV assays in monitoring the impact of HPV vaccination on disease burden.
人乳头瘤病毒是健康性活跃人群中最常见的生殖器病毒感染,生殖器细胞中慢性或持续性人乳头瘤病毒类型的存在可能构成潜在疾病的预后标志物,或预测未来与人乳头瘤病毒相关的疾病。已报道了多种用于检测生物标本中致癌性人乳头瘤病毒类型存在的新型检测方法。这些方法基于感染和病毒生命周期的不同阶段。人乳头瘤病毒感染鳞状上皮,其各种基因产物的表达与上皮细胞分化密切相关。因此,基本上有三类可直接源自人乳头瘤病毒的可检测标志物:基于核酸序列检测的分子标志物、基于针对病毒蛋白抗体检测的血清学标志物以及基于感染或致癌过程中细胞内表达蛋白检测的细胞标志物。概述了各种检测方法的性质以及用于定性和定量评估检测性能的国际标准试剂的开发情况。出于监管和临床管理目的,开发用于评估人乳头瘤病毒检测系统质量的标准工具的需求日益增加。人乳头瘤病毒国际标准试剂将有助于确定各种检测方法的分析灵敏度和特异性,并将确保用于评估疾病负担、人乳头瘤病毒疫苗和癌症预防策略的实验室服务在全球范围内准确且具有可比性。预防性人乳头瘤病毒感染及相关疾病疫苗候选物的进展凸显了人乳头瘤病毒检测在监测人乳头瘤病毒疫苗对疾病负担影响方面日益重要的作用。